Q-omics provides the consensus-scored GTPBP1 profile across patient tissues and cancer cell-line models. GTPBP1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GTPBP1 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, GTPBP1 protein abundance shows 23,306 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, LIHC, and PDAC as cancer lineages where GTPBP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTPBP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTPBP1 survival associations across molecular data types. GTPBP1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTPBP1 RNA expression–survival associations across cancer types. High GTPBP1 expression shows unfavorable associations in ACC, PAAD and LIHC, but favorable associations in SCLC, BRCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GTPBP1 RNA expression.
This table summarizes GTPBP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 8. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for GTPBP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTPBP1 shows lower tumor expression in LUAD and UCEC and higher tumor expression in LIHC, HNSC, CHOL and ESCA. The LIHC box plot shows higher GTPBP1 RNA expression in tumor versus normal tissue (log2 FC = +0.754, t-test p < 0.001).
This table shows molecular features associated with GTPBP1 in patient tissues and cancer cell lines. In patient samples, GTPBP1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, GTPBP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
